Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.intimp.2021.107522 http://scihub22266oqcxt.onion/10.1016/j.intimp.2021.107522 33735712!7951885!33735712     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+Immunopharmacol 2021 ; 95 (ä): 107522 Nephropedia Template TP {{tp|p=33735712|t=2021. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia |pdf=|usr=}}{{33735712}} gab.com Text Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia JO: Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33735712 #FOAvip BACKGROUND: We examined the safety and efficacy of a treatment protocol containing Favipiravir for the treatment of SARS-CoV-2. METHODS: We did a multicenter randomized open-labeled clinical trial on moderate to severe cases infections of SARS-CoV-2. Patients with typical ground glass appearance on chest computerized tomography scan (CT scan) and oxygen saturation (SpO(2)) of less than 93% were enrolled. They were randomly allocated into Favipiravir (1.6 gr loading, 1.8 gr daily) and Lopinavir/Ritonavir (800/200 mg daily) treatment regimens in addition to standard care. In-hospital mortality, ICU admission, intubation, time to clinical recovery, changes in daily SpO(2) after 5 min discontinuation of supplemental oxygen, and length of hospital stay were quantified and compared in the two groups. RESULTS: 380 patients were randomly allocated into Favipiravir (193) and Lopinavir/Ritonavir (187) groups in 13 centers. The number of deaths, intubations, and ICU admissions were not significantly different (26, 27, 31 and 21, 17, 25 respectively). Mean hospital stay was also not different (7.9 days [SD = 6] in the Favipiravir and 8.1 [SD = 6.5] days in Lopinavir/Ritonavir groups) (p = 0.61). Time to clinical recovery in the Favipiravir group was similar to Lopinavir/Ritonavir group (HR = 0.94, 95% CI 0.75 - 1.17) and likewise the changes in the daily SpO(2) after discontinuation of supplemental oxygen (p = 0.46) CONCLUSION: Adding Favipiravir to the treatment protocol did not reduce the number of ICU admissions or intubations or In-hospital mortality compared to Lopinavir/Ritonavir regimen. It also did not shorten time to clinical recovery and length of hospital stay. Twit Text FOAVip Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia ????Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33735712 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33735712 #FOAvip English Wikipedia <ref>{{Cite pmid|33735712}}</ref> Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia #MMPMID33735712 Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J Int Immunopharmacol 2021[Jun]; 95 (ä): 107522 PMID33735712show ga BACKGROUND: We examined the safety and efficacy of a treatment protocol containing Favipiravir for the treatment of SARS-CoV-2. METHODS: We did a multicenter randomized open-labeled clinical trial on moderate to severe cases infections of SARS-CoV-2. Patients with typical ground glass appearance on chest computerized tomography scan (CT scan) and oxygen saturation (SpO(2)) of less than 93% were enrolled. They were randomly allocated into Favipiravir (1.6 gr loading, 1.8 gr daily) and Lopinavir/Ritonavir (800/200 mg daily) treatment regimens in addition to standard care. In-hospital mortality, ICU admission, intubation, time to clinical recovery, changes in daily SpO(2) after 5 min discontinuation of supplemental oxygen, and length of hospital stay were quantified and compared in the two groups. RESULTS: 380 patients were randomly allocated into Favipiravir (193) and Lopinavir/Ritonavir (187) groups in 13 centers. The number of deaths, intubations, and ICU admissions were not significantly different (26, 27, 31 and 21, 17, 25 respectively). Mean hospital stay was also not different (7.9 days [SD = 6] in the Favipiravir and 8.1 [SD = 6.5] days in Lopinavir/Ritonavir groups) (p = 0.61). Time to clinical recovery in the Favipiravir group was similar to Lopinavir/Ritonavir group (HR = 0.94, 95% CI 0.75 - 1.17) and likewise the changes in the daily SpO(2) after discontinuation of supplemental oxygen (p = 0.46) CONCLUSION: Adding Favipiravir to the treatment protocol did not reduce the number of ICU admissions or intubations or In-hospital mortality compared to Lopinavir/Ritonavir regimen. It also did not shorten time to clinical recovery and length of hospital stay. |*COVID-19 Drug Treatment[MESH] |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Amides/*administration & dosage/*adverse effects[MESH] |Antiviral Agents/*administration & dosage/*adverse effects[MESH] |Drug Therapy, Combination[MESH] |Female[MESH] |Humans[MESH] |Hydroxychloroquine/administration & dosage/adverse effects[MESH] |Intubation[MESH] |Kaplan-Meier Estimate[MESH] |Length of Stay[MESH] |Lopinavir/administration & dosage/adverse effects[MESH] |Male[MESH] |Middle Aged[MESH] |Oxygen/blood[MESH] |Pyrazines/*administration & dosage/*adverse effects[MESH] |Ritonavir/administration & dosage/adverse effects[MESH] |Severity of Illness Index[MESH] |Treatment Outcome[MESH]Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pn(epmc).pdf DeepDyve Pubget Overpricing